OTC · Biotechnology

Celyad Oncology S.A. (CLYYF) Stock

$0.20 +0.00% OTC: CLYYF Healthcare

Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an allogeneic CAR-T candidate in a Phase 1b trial for metastatic colorectal cancer.

Valuation

MetricValue
Price$0.20
Market Cap$8.95M
P/E Ratio14.03
P/B Ratio4.91
P/S Ratio616.01
EPS (TTM)$0.01
52-Week High$0.53
52-Week Low$0.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-242.11%
ROA18.73%
ROCE-289.60%
Gross Margin61.90%
Operating Margin30414.29%
Net Margin3952.38%
Debt/Equity0.00
Current Ratio1.92

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-26.0M$-41.0M$-8.0M$-6.0M$-7.0M
Net Profit$-27.0M$-41.0M$-8.0M$-6.0M$1.0M
EPS$-1.70$-1.81$-0.33$-0.14$0.02
Op Margin——-8291.2%-3149.5%-34201.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$80.0M$20.0M$16.0M$10.0M$4.0M
Total Liabilities$36.0M$15.0M$10.0M$26.0M$2.0M
Cash$30.0M$12.0M$7.0M$4.0M$2.0M
Borrowings$3.0M$0$1.0M$18.0M$0

Latest News

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007) Business Wire · Jul 28, 2026 Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) Business Wire · Jul 22, 2026 Celyad Oncology Announces €500,000 Private Placement Business Wire · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-27.0M$-28.0M$-15.0M$-6.0M$-7.0M
Investing Cash Flow$-1.0M$7.0M$0$0$3.0M
Financing Cash Flow$41.0M$4.0M$10.0M$3.0M$0
Net Cash Flow$13.0M$-18.0M$-5.0M$-3.0M$-2.0M
Free Cash Flow$-27.0M$-28.0M$-16.0M$-6.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.10
EV / EBITDA-1.60
FCF Yield-53.34%
Quick Ratio1.92
Interest Coverage-112.22
Return 1Y-60.00%
Return 3Y-66.94%
Return 5Y—

Ownership

Insiders Held10.85%
Institutions Held58.59%
Institutions Float Held65.72%
Institutional HolderSharesReport Date
DFA Continental Small Company Series42,1902022-07-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADTX $0.01 -77.22% -0.01 $318 0.00%
ALLR $1.39 -0.71% -1.91 $22.12M 0.00%
BWVBlue Water Vaccines, Inc. $0.18 -6.97% -0.09 $3.41M 0.00%
CHNXFChitogenX Inc. $0.01 +0.00% -0.23 $627628 0.00%
CLAZFClaritas Pharmaceuticals, Inc. $0.00 — 0.00 $3659 0.00%

About Celyad Oncology S.A.

Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an allogeneic CAR-T candidate in a Phase 1b trial for metastatic colorectal cancer. Another significant asset is CYAD-211, an allogeneic CAR-T therapy based on short hairpin RNA (shRNA), currently undergoing Phase 1 evaluation for relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T candidate, is in Phase 1 trials for individuals with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Within its preclinical pipeline, the company is developing CYAD-203, a non-gene-edited allogeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for potential application in solid tumors. Celyad Oncology has established key collaborations, including a licensing agreement with Novartis International AG concerning U.S. patents for allogeneic CAR-T cells. It also maintains a research and development partnership, alongside licensing agreements, with Horizon Discovery Group plc to utilize their shRNA technology in creating a novel non-gene-edited allogeneic platform. Founded in 2004 as Celyad SA, the company rebranded to Celyad Oncology SA in June 2020 and is headquartered in Mont-Saint-Guibert, Belgium.

Celyad Oncology S.A. is headquartered in BE.

Celyad Oncology S.A. (CLYYF) stock trades at $0.20 with a market capitalization of $8.95M. The stock is valued at a price-to-earnings (P/E) ratio of 14.03, price-to-book of 4.91, price-to-sales of 616.01. Over the past 52 weeks the stock has ranged between $0.15 and $0.53, and currently trades 62.3% below its 52-week high.

On profitability, Celyad Oncology S.A. generates a return on equity (ROE) of -242.11%, return on capital employed of -289.60%, an operating margin of 30414.29%, a net profit margin of 3952.38%.

Official website: www.celyad.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides